About Zinc finger protein 449
Zinc finger protein 449 (ZNF449) is a protein
from Homo sapiens identified by UniProt accession
Q6P9G9, 518 residues long.
MolForge cross-references it against 0 known binders and
7 disease associations.
Target properties
| Protein name | Zinc finger protein 449 |
|---|
| UniProt accession | Q6P9G9 |
|---|
| Gene | ZNF449 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 518 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (7)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- Short stature · score 0.14
- colorectal cancer · score 0.01
- X-linked hyper-IgM syndrome · score 0.00
- Alzheimer disease · score 0.00
- cancer · score 0.00
- renal cell carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q6P9G9-F1 | alphafold | PREDICTED | 61.96 | — |
Amino-acid sequence (518 residues)
MAVALGCAIQ ASLNQGSVFQ EYDTDCEVFR QRFRQFQYRE AAGPHEAFNK LWELCCQWLK PKMRSKEQIL ELLVLEQFLT ILPTEIETWV REHCPENRER VVSLIEDLQR ELEIPEQQVD MHDMLLEELA PVGTAHIPPT MHLESPALQV MGPAQEAPVA EAWIPQAGPP ELNYGATGEC QNFLDPGYPL PKLDMNFSLE NREEPWVKEL QDSKEMKQLL DSKIGFEIGI ENEEDTSKQK KMETMYPFIV TLEGNALQGP ILQKDYVQLE NQWETPPEDL QTDLAKLVDQ QNPTLGETPE NSNLEEPLNP KPHKKKSPGE KPHRCPQCGK CFARKSQLTG HQRIHSGEEP HKCPECGKRF LRSSDLYRHQ RLHTGERPYE CTVCKKRFTR RSHLIGHQRT HSEEETYKCL ECGKSFCHGS SLKRHLKTHT GEKPHRCHNC GKSFSRLTAL TLHQRTHTEE RPFKCNYCGK SFRQRPSLVI HLRIHTGEKP YKCTHCSKSF RQRAGLIMHQ VTHFRGLI
Explore Zinc finger protein 449 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets